GLYC (GlycoMimetics) מקדם שווי פעילות להכנסות

סמלים רשמיים של חברת GlycoMimetics, Inc. (GLYC)

Due to the failure of leukemia drug trials, GlycoMimetics, Inc. (GLYC) has lost its pricing power and is undergoing restructuring. This EV/Revenue chart illustrates the valuation trend, where the current metric is . Business stability depends on the success of uproleselan and the inflow of capital to cover Phase 3 risks, while molecule discovery relies on the robotic analysis of biochemical reactions.

GlycoMimetics Inc. (GLYC): מכפיל EV/Sales מ-04.07.2022 עד 20.11.2026

פילוחי מדדים פיננסיים ומדדי שוק עבור GlycoMimetics Corp (GLYC)

- מחיר ותחזית קונצנזוס למחירים:
- מדדי הערכת שווי שוק של העסק:
הערכת שווי פונדמנטלית של החברה:GlycoMimetics Inc. GLYC
דוגמת מוצר של GlycoMimetics Inc.

Investors must monitor long-term risks by evaluating the enterprise value-to-revenue ratio, calculated as the ratio of total business capitalization to sales, excluding leverage. An upward trend on this chart signals inflated expectations, which is critical for GlycoMimetics, Inc. (GLYC), as its valuation depends on the successful integration of innovative glycomimetics into leukemia therapy standards.